Press Releases
Dec 19, 2022
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
Dec 13, 2022
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Nov 10, 2022
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 09, 2022
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
Nov 03, 2022
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
Oct 03, 2022
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
Sep 28, 2022
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
Sep 27, 2022
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
Sep 20, 2022
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease
Sep 16, 2022
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022